IRVINGTON, N.Y., Oct. 14, 2013 (GLOBE NEWSWIRE) -- MELA Sciences, Inc. (Nasdaq:MELA), the medical device company that has developed and is commercializing MelaFind®, the first and only FDA approved optical diagnostic device for melanoma detection used by dermatologists in their fight against melanoma, today announced that it will release its 2013 third quarter financial results after the close of trading on Wednesday, November 6, 2013. MELA Sciences' executives will also host a conference call that day at 4:30 PM ET to discuss the results, as well as provide a general business update.
| Date: | Wednesday, November 6, 2013 |
| Time: | 4:30 PM ET |
| To participate in the teleconference, please dial: | |
| Domestic toll-free: | (877) 303-9205 |
| International: | (760) 536-5226 |
To listen via live webcast, please go to the investor relations section of the MELA Sciences' website at http://www.melasciences.com approximately 10 minutes prior to the teleconference start time. If you are unable to participate during the live conference call and webcast, the conference call webcast will be archived and available for replay for approximately 90 days.
About MELA Sciences, Inc.
MELA Sciences is a medical device company focused on the commercialization of its flagship product, MelaFind®, and its further design and development. MelaFind is a non-invasive tool to provide additional information to dermatologists during melanoma skin examinations. The device uses light from visible to near-infrared wavelengths to evaluate skin lesions up to 2.5 mm beneath the skin. The device provides information on a lesion's level of morphologic disorganization to provide additional objective information that may be used by dermatologists in the biopsy decision-making process. MelaFind has been approved by the US Food and Drug Administration for use in the US. In addition, MelaFind has received CE Mark approval and is approved for use in the European Union.
For more information on MELA Sciences, visit www.melasciences.com.